Elvina Almuradova Shares Real-World NSCLC Treatment Outcomes Post Chemoimmunotherapy
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, posted on LinkedIn:
“New real-world evidence on treatment patterns and outcomes in advanced NSCLC after platinum-based chemotherapy and anti–PD-(L)1 therapy!
A recent retrospective cohort study (n=1793) published in JAMA sheds light on the treatment landscape and outcomes for patients with advanced/metastatic non–small cell lung cancer (NSCLC) in the US between 2018 and 2023.
Key Findings:
- Median TTD: 3.71 months
- Median PFS: 5.29 months
- Median OS: 11.2 months
Outcomes were shortest in patients receiving chemotherapy monotherapy (e.g. docetaxel, gemcitabine). Longest OS (26.97 months) was observed in patients receiving IO monotherapy (e.g. pembrolizumab) as index treatment. No dominant treatment approach emerged—131 different index regimens were used post anti–PD-(L)1 + platinum therapy. Patients with PD-L1 ≥50% were more common in the cohort that received first-line IO followed by chemotherapy (78.1%), reflecting biomarker-driven strategies.
The authors conclude: “There remains a significant unmet need in this patient population, especially for those progressing on standard chemoimmunotherapy.””
More posts featuring Elvina Almuradova.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023